LABGENOMICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,715 KRW | -0.91% |
|
+3.43% | -29.57% |
| Sales 2024 * | 111B 80.8M 6.74B | Sales 2025 * | 147B 106M 8.88B | Capitalization | 202B 146M 12.21B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.98 x |
| Net cash position 2024 * | 93B 67.52M 5.64B | Net cash position 2025 * | 99B 71.87M 6B | EV / Sales 2025 * | 0.7 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.25% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.91% | ||
| 1 week | +3.43% | ||
| Current month | -10.54% | ||
| 1 month | -9.65% | ||
| 3 months | -23.20% | ||
| 6 months | -20.85% | ||
| Current year | -29.57% |
1 week
2 700.00
2 760.00
1 month
2 510.003 130.00
Current year
2 510.004 265.00
1 year
2 510.006 500.00
3 years
2 510.007 000.00
5 years
663.339 633.33
10 years
663.339 633.33
| Managers | Title | Age | Since |
|---|---|---|---|
Seung-Hyun Jin
CEO | Chief Executive Officer | 56 | 29/02/29 |
Myung-Shin Kim
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/19/01 |
Yong-Sik Won
COO | Chief Operating Officer | 51 | 01/10/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seung-Hyun Jin
CEO | Chief Executive Officer | 56 | 29/02/29 |
Sung-Yong Ahn
BRD | Director/Board Member | 55 | 28/17/28 |
Won-Hui Hwang
BRD | Director/Board Member | 58 | 31/22/31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 2,715 | -0.91% | 377,059 |
| 25/24/25 | 2,740 | 0.00% | 297,090 |
| 24/24/24 | 2,740 | +0.92% | 325,132 |
| 23/24/23 | 2,715 | -0.18% | 439,146 |
| 22/24/22 | 2,720 | +3.62% | 2,556,832 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
LabGenomics Co., Ltd is a Korea-based company engaged in the provision of in vitro diagnostic (IVD) services. The Company mainly provides IVD services, including general diagnostic check services, molecular diagnostic check services, and research and development services. The Companyâs IVD products include deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) kits and others. It also provides examination for breast cancer and colorectal cancer, biosensor for point of care testing (POCT) and others. It also provides healthy food.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.57% | 146M | |
| -16.58% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -7.88% | 2.46B | |
| -8.95% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.03% | 1.03B |
- Stock Market
- Equities
- A084650 Stock
